Allergan Wants Out Of Restasis Patent Challenges
Allergan Inc. on Tuesday officially asked the Patent Trial and Appeal Board for permission to leave a series of patent challenges tied to its dry-eye medication Restasis, arguing it lost its...To view the full article, register now.
Already a subscriber? Click here to view full article